All three UK PNH agents cleared NICE's standard pathway, not the ultra-rare HST route, so dosing convenience now decides NHS share.

NHS England commissions PNH complement-inhibitor therapy through 15 Highly Specialised Services centres, concentrated at Leeds, King's, Oxford, Addenbrooke's, and Glasgow, for an estimated 600 diagnosed UK patients. Ravulizumab (Ultomiris) holds the NHS anchor position, having cleared NICE as a standard Technology Appraisal (TA698, published 19 May 2021) on the strength of its q8w dosing versus eculizumab's q2w regimen. Despite PNH's ultra-rare prevalence, ravulizumab did not use NICE's Highly Specialised Technology pathway. It met the standard TA cost-effectiveness bar at its negotiated NHS price, the same route the rest of the class has since followed.

Iptacopan (Fabhalta) has since cleared its own standard Technology Appraisal as TA1000, NICE's 1,000th published appraisal, with a final positive recommendation now in place. The access uncertainty around its estimated £350,000 to £400,000 annual WAC has been resolved in the drug's favour, and NHS access no longer runs through Individual Funding Request. Crovalimab (Piasky) has also been recommended by NICE, for patients aged 12 and over weighing at least 40kg, on the strength of COMMODORE 2 data. Its subcutaneous self-injection every four weeks is now a live convenience argument in market, not a pending one.

With access settled for all three, the fight moves to dosing convenience.

Five questions this report answers:

Q1 - Why did all three PNH agents clear NICE's standard route instead of the ultra-rare HST pathway?

Q2 - Which NHS centres control PNH prescribing, and how is the ravulizumab-over-eculizumab switch reshaping share?

Q3 - Now that iptacopan and crovalimab are both recommended, how does the convenience contest play out?

Q4 - How does ravulizumab's q8w dosing versus eculizumab's q2w regimen drive the NHS switch programme?

Q5 - What did resolving iptacopan's £350,000-400,000 annual WAC uncertainty mean for NHS access?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #UK #CompetitiveIntelligence #AXLRx #NICE #RareDisease

Live report page:  https://axlrx.ai/pnh/uk/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Iptacopan's orphan-drug status secured an established benefit and a substantial quality-of-life finding in Germany without a comparator dossier fight.

PNH has no confirmed German prevalence data of its own. The DGHO's Onkopedia guideline extrapolates instead from British and French registries, landing on an estimated 16 cases per million and 1.3 new diagnoses per million annually, and states plainly that Germany-specific figures do not exist. Diagnosis runs on GPI-anchor flow cytometry: at least two GPI-anchored markers must show deficient or reduced expression across at least two cell lineages. Two centres anchor the referral network: the German PNH-Register at Ulm's Institute for Clinical Transfusion Medicine and Immunogenetics, and the West German Cancer Center at University Hospital Essen. Both feed patients into the International PNH Registry.

Iptacopan's route to reimbursement skipped the standard AMNOG fight entirely. As an orphan-designated therapy, its additional benefit counted as established through EMA approval, so IQWiG never had to build a head-to-head dossier against anti-C5 therapy. The G-BA went further on 19 December 2024, finding a substantial additional benefit specifically on quality of life for patients switching from anti-C5 therapy, and in March 2025 declined to require accompanying data collection. Crovalimab has no such shortcut: its dossier, submitted 12 September 2024, remains under active IQWiG assessment. Ravulizumab's only Germany-specific finding found no additional benefit against eculizumab.

Future anti-C5 entrants face the comparator dossier fight iptacopan skipped entirely.

Five questions this report answers:

Q1 - What does the orphan pathway actually establish, and what evidentiary bar did iptacopan skip?

Q2 - Where does German PNH referral concentrate, and how is the addressable population sized without a confirmed national count?

Q3 - What is crovalimab's AMNOG status today, and what does ravulizumab's 2022 pediatric rejection signal?

Q4 - How does Germany's AMNOG/G-BA framework shape PNH market access for future anti-C5 entrants?

Q5 - Why did the G-BA decline to require a parallel data-collection registry for iptacopan?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #Germany #AMNOG #GBA #Iptacopan #MarketAccess

Live report page:  https://axlrx.ai/pnh/germany/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary, and fewer than 15 labs across six countries can diagnose PNH.

Anti-C5 complement inhibitors, eculizumab (Soliris) and ravulizumab (Ultomiris), both AstraZeneca/Alexion, are the GCC standard of care for PNH, covered under Saudi Arabia's national rare genetic disease programme and the UAE Ministry of Health rare-disease formulary. Access is gated by specialist-centre designation: patients with confirmed PNH, defined by elevated LDH plus a FLAER-positive clone of 10% or more, are treated only at four institutions, King Abdulaziz Medical City and King Faisal Specialist Hospital in Riyadh, Abu Dhabi's AUH, and Rashid Hospital in Dubai, concentrating the addressable population and creating a real travel burden for patients outside those cities.

Novartis's iptacopan (Fabhalta), FDA-approved in 2023 on an 82.3% haemoglobin-responder rate in APPLY-PNH, has not reached a single GCC formulary as of this writing. SFDA and MOHAP registration for novel rare-disease agents typically lags FDA/EMA approval by 12 to 24 months, and current access runs through named-patient compassionate use at select centres only. The Saudi National Rare Disease Registry tracks roughly 400 confirmed PNH cases, but consanguinity rates of 25-50% across KSA, UAE, and Qatar likely elevate true prevalence 20-30% above the global average, and fewer than 15 laboratories across all six GCC states offer FLAER flow cytometry.

Whoever registers iptacopan first captures a diagnosis-starved, under-treated GCC PNH population.

Five questions this report answers:

Q1 - Which GCC specialist centres and NPHC/MOH criteria gate access to anti-C5 therapy today?

Q2 - When will iptacopan reach SFDA/MOHAP registration and NPHC formulary listing?

Q3 - How does the FLAER diagnostic bottleneck change the addressable patient math for a new entrant?

Q4 - How does the SFDA/MOHAP registration lag affect the shift from anti-C5 IV therapy to oral inhibition?

Q5 - What would a formal switch protocol from anti-C5 IV therapy to oral Factor B inhibition require?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #GCC #Iptacopan #RareDisease #ComplementInhibitor #MarketAccess

Live report page:  https://axlrx.ai/pnh/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

HAS restricted iptacopan to second-line use, anemic patients below 10 g/dL haemoglobin after six months on anti-C5 therapy.

France's Commission de la Transparence rated iptacopan (Fabhalta) ASMR III, a moderate improvement, in its 5 December 2024 economic opinion. That rating came with a restriction the FDA and MHRA labels do not carry: HAS positions iptacopan as a second-line option only, for adult patients with persistent hemolytic anemia, haemoglobin below 10 g/dL, after at least six months on a C5 complement inhibitor. Ravulizumab (Ultomiris) holds the opposite position: its SMR is rated important, and HAS considers it a first-line medicine for PNH, citing its every-eight-week dosing advantage over eculizumab's every-two-week schedule. Ravulizumab defends first place; iptacopan has to earn its way in from second line.

That asymmetry sets the CEPS price negotiation up differently for each drug. Iptacopan's published reimbursement price is €29,590.96 excluding tax per box of 56 tablets, negotiated against a target population the manufacturer itself estimated at only 270 patients nationally, a genuinely small commercial base for a specialty price point. Ravulizumab's published price runs €14,988.66 for the 1100mg vial and €4,087.82 for the 300mg vial, reflecting weight-based dosing across a first-line population that never had to argue past a prior-treatment gate. France's second-line restriction shrinks iptacopan's addressable population before a single euro of price negotiation happens.

France shrinks iptacopan's addressable population before a euro of pricing is negotiated.

Five questions this report answers:

Q1 - Why did HAS restrict iptacopan to second-line use when the US and UK labels don't?

Q2 - What does a target population of just 270 patients imply for the CEPS price negotiation?

Q3 - How does ravulizumab's first-line SMR-important position change the comparator argument for new entrants?

Q4 - What does the second-line restriction mean for iptacopan's addressable population and CEPS pricing?

Q5 - What dosing advantage did HAS cite to keep ravulizumab in the first-line position?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #France #HAS #ASMR #Iptacopan #MarketAccess

Live report page:  https://axlrx.ai/pnh/france/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Tirzepatide delivered 20.9% weight loss versus semaglutide's 15.3%, but Medicare Part D still excludes anti-obesity drugs for 50 million beneficiaries.

Approximately 100 million US adults meet the diagnostic threshold for obesity, BMI 30 or above, and roughly 22 million have severe obesity, BMI 40 or above. Two GLP-1-based injectables dominate the treatment landscape: semaglutide 2.4mg (Wegovy, Novo Nordisk, approved June 2021) and tirzepatide (Zepbound, Eli Lilly, approved November 2023). Tirzepatide's SURMOUNT-1 trial demonstrated 20.9% weight loss against semaglutide's STEP 1 result of 15.3%, establishing a clear head-to-head efficacy advantage for the newer agent.

Medicare Part D has historically excluded anti-obesity medications, leaving roughly 50 million Medicare beneficiaries without prescription coverage. A proposed 2025 CMS rule to allow GLP-1 agents under Part D remains pending congressional action. Commercial payers require a BMI of 30 or above with at least one comorbidity, or a BMI of 35 or above alone, before granting prior authorization, creating substantial access barriers. Supply constraints for Wegovy persisted through 2023 and have partially eased by mid-2024.

Efficacy superiority means little while the largest payer, Medicare, still excludes the category.

Five questions this report answers:

Q1 - How are UHC, CVS/Aetna and Cigna differentiating prior authorization criteria between tirzepatide and semaglutide?

Q2 - What is the commercial impact of the proposed 2025 CMS rule allowing Medicare Part D GLP-1 coverage?

Q3 - Which pipeline oral agents, orforglipron and danuglipron, threaten injectable dominance in obesity by 2027?

Q4 - What BMI and comorbidity thresholds do commercial payers require before granting obesity drug prior authorization?

Q5 - How many of the roughly 100 million eligible US adults remain blocked by the Medicare Part D exclusion?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Obesity #US #CompetitiveIntelligence #AXLRx #GLP1

Live report page:  https://axlrx.ai/obesity/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Pembrolizumab holds an estimated 52% share of first-line NSCLC, splitting the market into three PD-L1 cohorts ahead of its 2028 patent expiry.

Four approved immuno-oncology agents have divided the first-line NSCLC patient pool into distinct PD-L1 biomarker cohorts, each with a different dominant agent and different payer coverage criteria. Pembrolizumab controls the PD-L1 50% or greater monotherapy setting through five years of clinical and commercial precedent, holding an estimated 52% share, while combination regimens have set a different standard below that threshold. These cohorts are not interchangeable, and a single commercial strategy cannot address both.

US payer coverage criteria for immuno-oncology agents in NSCLC were written around the early KEYNOTE and CheckMate trials, and new entrants are evaluated against those precedents rather than their own trial designs. The evidence a payer will require at approval is already visible in existing coverage policies, and the window to shape that conversation runs 12 to 18 months pre-approval, not at launch. Mapping that landscape early is what lets a commercial team lock in position before strategy is set.

The coverage bar for a new entrant is set by precedent, not by its own trial design.

Five questions this report answers:

Q1 - What is the addressable NSCLC patient pool by PD-L1 cohort and line of therapy over five years?

Q2 - Which agents control which PD-L1 cohorts, and what clinical differentiation has actually moved prescribing share?

Q3 - What evidence thresholds are US payers applying, and does a new asset's trial design clear them?

Q4 - Where are the unmet needs current IO agents have not addressed among non-responder and progression cohorts?

Q5 - What are realistic patient-capture scenarios at Year 1, Year 3 and Year 5 by PD-L1 cohort?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#NSCLC #US #CompetitiveIntelligence #AXLRx #Oncology

Live report page:  https://axlrx.ai/nsclc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Three novel mechanisms reached US gMG in 24 months, and the AChR-antibody line decides which patients the C5 class can even reach.

Generalised myasthenia gravis is now a multi-mechanism market. The FcRn antagonists lower pathogenic IgG and carry broad labels with no complement-restricting serology requirement: efgartigimod (Vyvgart/Vyvgart Hytrulo, argenx) and rozanolixizumab (Rystiggo, UCB), both approved in 2023. The complement class splits by route: the IV C5 inhibitors eculizumab (Soliris) and ravulizumab (Ultomiris) from AstraZeneca/Alexion, and UCB's subcutaneous zilucoplan (Zilbrysq). Efgartigimod anchored the FcRn entry with a 68% MG-ADL responder rate versus 30% on placebo in the ADAPT trial.

The competitive story turns on two forces. Roughly 85% of gMG patients are AChR-antibody positive, and the C5 inhibitors are approved only in that subgroup, so MuSK-positive and seronegative patients, about 15% of the market, are reachable only by the FcRn class. UCB holds both an FcRn antagonist and a C5 inhibitor, so it participates on whichever side of the FcRn-versus-complement sequence a payer imposes, a dual-asset position no other manufacturer shares.

Antibody serology, not brand loyalty, decides which mechanism a patient can even access.

Five questions this report answers:

Q1 - How do the FcRn antagonists and C5 inhibitors differentiate on mechanism, route and serology eligibility?

Q2 - What does UCB's dual-asset position in both FcRn and C5 mean for its competitive strategy?

Q3 - How is AChR-positive versus MuSK-positive and seronegative segmentation reshaping targeting and share in gMG?

Q4 - Why can the roughly 15% of MuSK-positive and seronegative patients only be reached by the FcRn class?

Q5 - What did the ADAPT trial show for efgartigimod's MG-ADL responder rate against placebo?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #US #CompetitiveIntelligence #AXLRx #RareDisease

Live report page:  https://axlrx.ai/myasthenia-gravis/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

NICE rejected efgartigimod outright in 2025, leaving rozanolixizumab as the FcRn class's one still-untested bid for UK access.

An estimated 7,000-10,000 UK patients have generalised myasthenia gravis, with roughly 4,000 having moderate-to-severe disease eligible for novel agents. Eculizumab's (Soliris, AstraZeneca) UK appraisal, TA636, was terminated by NICE in June 2020 after the manufacturer withdrew without submitting cost-effectiveness evidence, leaving refractory patients dependent on Individual Funding Request exceptional-case access only. No cost-per-QALY figure was ever published: this was a manufacturer decision not to pursue UK reimbursement, not a rejection on value grounds. This remains the widest NICE access gap among the UK rare-disease markets in this set: no novel biologic is currently NHS-commissioned for generalised myasthenia gravis.

NICE rejected efgartigimod alfa (Vyvgart/Vyvgart Hytrulo, argenx) for generalised myasthenia gravis in its June 2025 final guidance (TA1069), the first FcRn-antagonist verdict in the class. UK neurology centres continue to access efgartigimod for severe refractory patients via Named Patient Programme, with an estimated 200 UK patients reached this way despite the negative TA. Rozanolixizumab (Rystiggo, UCB) is now the FcRn-antagonist class's one remaining live NICE bid: a positive recommendation with an agreed PAS would be the first transformative access event for the class in the UK, opening NHS commissioning at an estimated 25 specialist neuromuscular centres.

No novel biologic is yet NHS-commissioned for this 4,000-patient eligible population.

Five questions this report answers:

Q1 - What cost-effectiveness evidence would let rozanolixizumab succeed where efgartigimod was rejected in 2025?

Q2 - How is argenx sustaining a 200-patient Named Patient Programme after NICE's 2025 rejection?

Q3 - Which of the ~25 UK neuromuscular centres would first commission rozanolixizumab on a positive verdict?

Q4 - Why was eculizumab's TA636 appraisal withdrawn in 2020 rather than rejected on cost?

Q5 - How many of the UK's 7,000-10,000 gMG patients are eligible for novel agents?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #UK #CompetitiveIntelligence #AXLRx #NICE #RareDisease

Live report page:  https://axlrx.ai/myasthenia-gravis/uk/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Efgartigimod reached GCC neurology centres in 2023, yet pyridostigmine and steroids still anchor treatment for more than 85% of patients.

Pyridostigmine plus corticosteroids or azathioprine remains the dominant regimen for an estimated 85% or more of GCC myasthenia gravis patients, a generic backbone that is MOH formulary listed and universally available. Diagnosis is the first bottleneck: AChR antibody testing is available at roughly 20 centres across the six GCC states, concentrated in Riyadh, Dubai, Abu Dhabi, and Doha, and presentation is frequently delayed because clinicians attribute ptosis or diplopia to the region's high rates of thyroid disease rather than to myasthenia gravis. Anti-MuSK antibody testing is available at even fewer sites, leaving many seronegative and MuSK-positive patients under-characterised.

Efgartigimod (Vyvgart), argenx's FcRn antagonist, registered with SFDA and UAE MOH in 2023 and is now available at KFSH&RC, AUH, and Hamad Medical Corporation through argenx's GCC distribution partnership with Takeda, the first novel MG mechanism to reach the region. Uptake stands at an estimated 200 to 300 patients as of mid-2024, almost entirely refractory generalised MG failing pyridostigmine, steroids, and azathioprine. Eculizumab is technically registered for refractory AChR-positive gMG via its existing PNH approval but sees very low utilisation, since NPHC has not established MG-specific coverage criteria.

Formulary inclusion, not clinical proof, decides when the FcRn class reaches standard care.

Five questions this report answers:

Q1 - Which NPHC and MOH UAE formulary criteria govern efgartigimod access today?

Q2 - Which GCC neurology centres prescribe efgartigimod, and what does the AChR testing gap mean for switch-eligible patients?

Q3 - Why does eculizumab see minimal MG utilisation in GCC despite registration?

Q4 - Why hasn't efgartigimod displaced the pyridostigmine-steroid backbone despite its 2023 SFDA registration?

Q5 - How many GCC patients remain on generic pyridostigmine while FcRn formulary criteria are still being written?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #GCC #FcRn #Efgartigimod #RareDisease #MarketAccess

Live report page:  https://axlrx.ai/myasthenia-gravis/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Wegovy won MASH approval in August 2025, turning a pre-launch window into a Year 0 to Year 1 retention fight against Rezdiffra.

MASH, the progressive inflammatory form of fatty liver disease, was renamed from NASH under the 2023 multi-society consensus. The FDA-defined treatable population is US adults with noncirrhotic MASH and moderate-to-advanced fibrosis, stages F2 to F3, roughly 6.7 million people. Two drugs now hold FDA accelerated approval for that exact label: Rezdiffra (resmetirom), an oral THR-beta agonist from Madrigal, approved March 2024, and Wegovy (semaglutide 2.4mg), a GLP-1 from Novo Nordisk, approved August 2025.

The common assumption that semaglutide is a future 2027 entrant is wrong: it is already competing with Rezdiffra today. On their placebo-controlled endpoints, semaglutide shows stronger resolution, 62.9% versus 34.3%, and greater weight loss, while Rezdiffra's defensible ground is its direct fibrosis-targeted mechanism, oral convenience and an earlier Medicare price-negotiation horizon under the IRA. The strategic move is to lock preferred formulary tier and first-line prior authorization tied to FIB-4 or elastography-confirmed fibrosis before GLP-1 data harden guideline preference.

The oral, liver-specific mechanism is easier to wall off than a GLP-1 with obesity spillover demand.

Five questions this report answers:

Q1 - Is the semaglutide threat still ahead of us, or is Wegovy already competing with Rezdiffra today?

Q2 - Where does Rezdiffra still win a clinical argument against semaglutide's stronger resolution and weight-loss data?

Q3 - How can commercial teams lock preferred payer access before GLP-1 data shift guideline preference?

Q4 - Why does resmetirom face an earlier IRA Medicare price-negotiation clock than a biologic GLP-1?

Q5 - Which pipeline agents, including lanifibranor and the FGF21 class, are chasing the compensated-cirrhosis segment neither drug covers?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MASH #US #CompetitiveIntelligence #AXLRx #LiverDisease

Live report page:  https://axlrx.ai/mash/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/